{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:43Z","timestamp":1791689563553,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022502","name":"Mereo BioPharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03373-7","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:36:19Z","timestamp":1758612979000},"page":"5761-5780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The IMPACT Survey: The Economic Impact of Caring for an Individual with Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"42","author":[{"given":"Frank","family":"Rauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco","family":"van Welzenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Lande","family":"Wekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen","family":"Raggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Semler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Westerheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Mulhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"12","key":"3373_CR1","doi-asserted-by":"publisher","first-page":"S542","DOI":"10.1016\/j.jval.2024.10.3427","volume":"27","author":"S Prince","year":"2024","unstructured":"Prince S, van Welzenis T, Wekre LL, et al. Comparing the humanistic and economic impact of osteogenesis imperfecta affected and non-affected caregivers, who care for an individual with osteogenesis imperfecta. Value Health. 2024;27(12):S542\u20133.","journal-title":"Value Health"},{"key":"3373_CR2","unstructured":"Bishop N. Osteogenesis imperfecta. Orphanet. 2021. https:\/\/www.orpha.net\/en\/disease\/detail\/666. Accessed 11 Dec 2024."},{"key":"3373_CR3","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2016.14322","volume":"146","author":"A Bregou Bourgeois","year":"2016","unstructured":"Bregou Bourgeois A, Aubry-Rozier B, Bonaf\u00e9 L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016;146:w14322.","journal-title":"Swiss Med Wkly"},{"issue":"10028","key":"3373_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657\u201371.","journal-title":"Lancet"},{"issue":"6","key":"3373_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164A","author":"FS Van Dijk","year":"2014","unstructured":"Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470\u201381.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"3373_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316.","journal-title":"J Med Genet"},{"key":"3373_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"3373_CR8","first-page":"5454","volume":"65","author":"L Folkestad","year":"2018","unstructured":"Folkestad L. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark. Danish Med J. 2018;65(4):5454.","journal-title":"Danish Med J"},{"issue":"1","key":"3373_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","volume":"32","author":"L Folkestad","year":"2017","unstructured":"Folkestad L, Hald JD, Ersboll AK, et al. Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res. 2017;32(1):125\u201334.","journal-title":"J Bone Miner Res"},{"key":"3373_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101493","author":"M Botor","year":"2021","unstructured":"Botor M, Fus-Kujawa A, Uroczynska M, et al. Osteogenesis imperfecta: current and prospective therapies. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11101493.","journal-title":"Biomolecules"},{"issue":"8","key":"3373_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10174","volume":"3","author":"JT Tauer","year":"2019","unstructured":"Tauer JT, Robinson ME, Rauch F. Osteogenesis imperfecta: new perspectives from clinical and translational research. JBMR plus. 2019;3(8):e10174.","journal-title":"JBMR plus"},{"issue":"10","key":"3373_CR12","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10(10):CD005088.","journal-title":"Cochrane Database Syst Rev"},{"key":"3373_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JMDH.S113483","volume":"10","author":"C Marr","year":"2017","unstructured":"Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc. 2017;10:145\u201355.","journal-title":"J Multidiscip Healthc"},{"issue":"4","key":"3373_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4055\/cios20060","volume":"12","author":"TJ Cho","year":"2020","unstructured":"Cho TJ, Ko JM, Kim H, Shin HI, Yoo WJ, Shin CH. Management of osteogenesis imperfecta: a multidisciplinary comprehensive approach. Clin Orthop Surg. 2020;12(4):417\u201329.","journal-title":"Clin Orthop Surg"},{"issue":"2","key":"3373_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491\u20138.","journal-title":"J Clin Invest"},{"issue":"1","key":"3373_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-023-02627-3","volume":"18","author":"M Rapoport","year":"2023","unstructured":"Rapoport M, Bober MB, Raggio C, et al. The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review. Orphanet J Rare Dis. 2023;18(1):34.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3373_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2431-13-153","volume":"13","author":"MJ Dogba","year":"2013","unstructured":"Dogba MJ, Bedos C, Durigova M, et al. The impact of severe osteogenesis imperfecta on the lives of young patients and their parents\u2014a qualitative analysis. BMC Pediatr. 2013;13(1):153.","journal-title":"BMC Pediatr"},{"key":"3373_CR18","doi-asserted-by":"publisher","unstructured":"Castro A, Morand M, Rauch F, Tsimicalis A. The direct and indirect financial costs sustained by parents of children with osteogenesis imperfecta: a brief report. McGill J Med. 2022;20(1). https:\/\/doi.org\/10.26443\/mjm.v20i1.831.","DOI":"10.26443\/mjm.v20i1.831"},{"issue":"1","key":"3373_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13023-024-03218-6","volume":"19","author":"T Hart","year":"2024","unstructured":"Hart T, Westerheim I, van Welzenis T, et al. The IMPACT survey: the economic impact of osteogenesis imperfecta in adults. Orphanet J Rare Dis. 2024;19(1):222.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3373_CR20","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1186\/s12889-024-20555-0","volume":"24","author":"T van Welzenis","year":"2024","unstructured":"van Welzenis T, Westerheim I, Hart T, et al. The IMPACT survey: the humanistic impact of osteogenesis imperfecta in adults. BMC Public Health. 2024;24(1):3318.","journal-title":"BMC Public Health"},{"issue":"1","key":"3373_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-024-03126-9","volume":"19","author":"I Westerheim","year":"2024","unstructured":"Westerheim I, Hart T, van Welzenis T, et al. The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers. Orphanet J Rare Dis. 2024;19(1):128.","journal-title":"Orphanet J Rare Dis"},{"key":"3373_CR22","unstructured":"UK Research Integrity Office. Good practice in research: Internet-mediated research. 2016. https:\/\/ukrio.org\/wp-content\/uploads\/UKRIO-Guidance-Note-Internet-Mediated-Research-v1.0.pdf. Accessed 11 Dec 2024."},{"key":"3373_CR23","unstructured":"Association EPMR. Code of Conduct. 2024."},{"key":"3373_CR24","unstructured":"Commerce ICo. ICC\/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics. 2025."},{"key":"3373_CR25","unstructured":"REGULATION (EU) 2016\/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation), 2016\/679 (2016)."},{"key":"3373_CR26","unstructured":"OECD. Unemployment rate (indicator). Key short term economic indicators. https:\/\/www.oecd.org\/en\/data\/indicators\/unemployment-rate.html. Accessed 09 Dec 2024."},{"key":"3373_CR27","unstructured":"OECD. Part-time employment rate. Key short-term economic indicators. https:\/\/www.oecd.org\/en\/data\/indicators\/part-time-employment-rate.html. Accessed 09 Dec 2024."},{"key":"3373_CR28","unstructured":"Wilmot A LD. Sickness absence in the UK labour market 2021. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/labourproductivity\/articles\/sicknessabsenceinthelabourmarket\/2021. Accessed 09 Dec 2024."},{"key":"3373_CR29","first-page":"2023","volume":"18","author":"M Bratley","year":"2023","unstructured":"Bratley M. A third of parents forced to take unpaid leave due to their sick child\u2014MetLife UK. IFA Mag. 2023;18:2023.","journal-title":"IFA Mag"},{"issue":"4","key":"3373_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/HTR.0000000000000458","volume":"34","author":"RE Nelson","year":"2019","unstructured":"Nelson RE, Ma J, Cheng Y, Ewing-Cobbs L, Clark A, Keenan H. Healthcare utilization and missed workdays for parents of children with traumatic brain injury. J Head Trauma Rehabil. 2019;34(4):257\u201367.","journal-title":"J Head Trauma Rehabil"},{"issue":"7","key":"3373_CR31","first-page":"764","volume":"65","author":"LB Arabaci","year":"2015","unstructured":"Arabaci LB, Bozkurt S, Vara S, Ozen S, Darcan S, Simsek DG. Difficulties experienced by caregivers of patients diagnosed with osteogenesisimperfecta (OI): example of a hospital. J Pak Med Assoc. 2015;65(7):764\u201370.","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"3373_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JOP.2014.001495","volume":"11","author":"EL Warner","year":"2015","unstructured":"Warner EL, Kirchhoff AC, Nam GE, Fluchel M. Financial burden of pediatric cancer for patients and their families. J Oncol Pract. 2015;11(1):12\u20138.","journal-title":"J Oncol Pract"},{"issue":"2","key":"3373_CR33","first-page":"309","volume":"74","author":"J Swinkels","year":"2017","unstructured":"Swinkels J, Tilburg TV, Verbakel E, van Broese Groenou M. Explaining the gender gap in the caregiving burden of partner caregivers. J Gerontol Series B. 2017;74(2):309\u201317.","journal-title":"J Gerontol Series B"},{"issue":"1","key":"3373_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-022-02561-w","volume":"17","author":"K Sandilands","year":"2022","unstructured":"Sandilands K, Williams A, Rylands AJ. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet J Rare Dis. 2022;17(1):428.","journal-title":"Orphanet J Rare Dis"},{"issue":"15\u201316","key":"3373_CR35","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1111\/jocn.15310","volume":"29","author":"AR Castro","year":"2020","unstructured":"Castro AR, Marinello J, Chougui K, Morand M, Bilodeau C, Tsimicalis A. The day-to-day experiences of caring for children with osteogenesis imperfecta: a qualitative descriptive study. J Clin Nurs. 2020;29(15\u201316):2999\u20133011.","journal-title":"J Clin Nurs"},{"issue":"5","key":"3373_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/1475-6773.13858","volume":"56","author":"P Herd","year":"2021","unstructured":"Herd P, Moynihan D. Health care administrative burdens: centering patient experiences. Health Serv Res. 2021;56(5):751\u20134.","journal-title":"Health Serv Res"},{"issue":"5","key":"3373_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","volume":"38","author":"ST Syed","year":"2013","unstructured":"Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Commun Health. 2013;38(5):976\u201393.","journal-title":"J Commun Health"},{"issue":"187\u201393","key":"3373_CR38","volume":"172","author":"J Thomson","year":"2016","unstructured":"Thomson J, Shah SS, Simmons JM, et al. Financial and social hardships in families of children with medical complexity. J Pediatr. 2016;172(187\u201393):e1.","journal-title":"J Pediatr"},{"key":"3373_CR39","unstructured":"Evans J, Collard S. Under pressure: the financial wellbeing of UK households in June 2022. Financial Fairness Trust: University of Bristol; 2022."},{"issue":"1","key":"3373_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/beheco\/arac105","volume":"34","author":"JA Brand","year":"2023","unstructured":"Brand JA, Henry J, Melo GC, Wlodkowic D, Wong BBM, Martin JM. Sex differences in the predictability of risk-taking behavior. Behav Ecol. 2023;34(1):108\u201316.","journal-title":"Behav Ecol"},{"key":"3373_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13023-015-0362-2","volume":"10","author":"LL Tosi","year":"2015","unstructured":"Tosi LL, Oetgen ME, Floor MK, et al. Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis. 2015;10:146.","journal-title":"Orphanet J Rare Dis"},{"key":"3373_CR42","unstructured":"Bunch L, Ketema H, Keisler-Starkey K. How age and poverty level impact health insurance coverage. United States Census Bureau: 2024. https:\/\/www.census.gov\/library\/stories\/2024\/09\/health-insurance-coverage.html. Accessed 12 Dec 2024."},{"key":"3373_CR43","unstructured":"Lind Y. Childcare infrastructure in the Nordic Countries. 2024. https:\/\/nordics.info\/show\/artikel\/childcare-infrastructure-in-the-nordic-countries. Accessed 12 Dec 2024."},{"key":"3373_CR44","unstructured":"OECD. Parental leave systems. 2024. https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/data\/datasets\/family-database\/pf2_1_parental_leave_systems.pdf. Accessed 09 Dec 2024."},{"issue":"4","key":"3373_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0958928720921346","volume":"30","author":"J Vinck","year":"2020","unstructured":"Vinck J, Brekke I. Gender and education inequalities in parental employment and earnings when having a child with increased care needs: Belgium versus Norway. J Eur Soc Policy. 2020;30(4):495\u2013508.","journal-title":"J Eur Soc Policy"},{"key":"3373_CR46","doi-asserted-by":"publisher","first-page":"205031211562379","DOI":"10.1177\/2050312115623792","volume":"4","author":"KE Baird","year":"2016","unstructured":"Baird KE. The financial burden of out-of-pocket expenses in the United States and Canada: how different is the United States? SAGE Open Med. 2016;4:2050312115623792.","journal-title":"SAGE Open Med"},{"issue":"1","key":"3373_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12913-018-3185-8","volume":"18","author":"T Rice","year":"2018","unstructured":"Rice T, Quentin W, Anell A, et al. Revisiting out-of-pocket requirements: trends in spending, financial access barriers, and policy in ten high-income countries. BMC Health Serv Res. 2018;18(1):371.","journal-title":"BMC Health Serv Res"},{"key":"3373_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.636750","volume":"9","author":"D Montagu","year":"2021","unstructured":"Montagu D. The provision of private healthcare services in European countries: recent data and lessons for universal health coverage in other settings. Front Public Health. 2021;9:636750.","journal-title":"Front Public Health"},{"key":"3373_CR49","unstructured":"Peter G. Peterson Foundation. How does the US healthcare system compare to other countries? Peter G. Peterson Foundation; 2024. https:\/\/www.pgpf.org\/article\/how-does-the-us-healthcare-system-compare-to-other-countries\/. Accessed 14 Jan 2025."},{"issue":"49","key":"3373_CR50","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.15585\/mmwr.mm6949e2","volume":"69","author":"MA Honein","year":"2020","unstructured":"Honein MA, Christie A, Rose DA, et al. Summary of guidance for public health strategies to address high levels of community transmission of SARS-CoV-2 and related deaths, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(49):1860\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"3373_CR51","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, \u00c5str\u00f6m E, Rubin C-J, et al. Genetic epidemiology, prevalence, and genotype\u2013phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015;23(8):1042\u201350.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"3373_CR52","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12913-024-11191-w","volume":"24","author":"D Pacheco Barzallo","year":"2024","unstructured":"Pacheco Barzallo D, Schnyder A, Zanini C, Gemperli A. Gender differences in family caregiving. Do female caregivers do more or undertake different tasks? BMC Health Serv Res. 2024;24(1):730.","journal-title":"BMC Health Serv Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03373-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:31:25Z","timestamp":1762263085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3373"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03373-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heather Mulhall and Melanie Anderson are employees of Wickenstones Ltd, Oxford, UK. Samantha Prince is an employee of Mereo BioPharma Group London, UK. At the time of the survey design and development of this research, Samantha Prince was an employee of Wickenstones Ltd. Ingunn Westerheim, Tracy Hart, Taco van Welzenis, Lena Lande Wekre, Oliver Semler, Cathleen Raggio, and Frank Rauch have provided expert consulting to Mereo BioPharma Group London, UK. Tracy Hart serves as the Chief Executive Officer of the Osteogenesis Imperfecta Foundation, who have received unrestricted educational grants from Mereo BioPharma Group London, UK and Ultragenyx Pharmaceuticals Inc, Novato, USA. Oliver Semler has participated in a national advisory board for Mereo BioPharma Group London, UK and has received study contracts for clinical studies from Ultragenyx Pharmaceuticals Inc, Novato, USA. Frank Rauch has received study contracts for experimental preclinical studies with Precithera Inc, Quebec, Canada, Mesentech Inc, Vancouver, Canada and Catabasis Pharmaceuticals Inc, Cambridge, USA. He has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA, Sanofi S.A. Paris, France, Novartis International AG, Basel, Switzerland and Mereo BioPharma Group, London, UK. Frank Rauch has received a speaker fee from Ultragenyx Pharmaceuticals Inc, Novato, USA for a lecture and received a donation of experimental drugs for a preclinical study from Acceleron Pharma Inc, Cambridge, USA. Cathleen Raggio received an institutional grant from and has been a speaker for BioMarin Pharmaceuticals Inc, Novato, California, has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA. She has received an institutional grant from and is a consultant for Nextcure, Beltville, MD, USA. Cathleen Raggio sits on the board of directors of the Osteogenesis Imperfecta Foundation. Cathleen Raggio has also participated in an advisory board for Mereo BioPharma Group, London, UK. Taco van Welzenis and Ingunn Westerheim hold leadership positions in the Osteogenesis Imperfecta Federation Europe, which has received grants from Mereo BioPharma Group, London, UK (unrestricted), Ultragenyx Pharmaceuticals Inc, Novato, USA (restricted grant for a conference), Quince Therapeutics Inc, San Francisco, CA, USA (donation for a conference), UCB (restricted grant to conference), Angitia Biopharmaceuticals Inc., Woodland Hills, CA, USA (donation to conference), Azafaros BV, Naarden, the Netherlands (donation to conference), Alexion Inc. Boston, MA, USA, (sponsorship of conference); Pega Medical Inc, Laval, Quebec, Canada (donation), PuREC, Shimane, Japan (sponsorship of conference) and Takeda, Tokyo, Japan (payment to Ingunn Westerheim as a panellist; donated to OIFE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The need for informed consent was waived, and an ethics approval exemption was granted for this study by Pearl IRB Indianapolis, IN, USA, (registered with OHRP and FDA; organisation number 0006471, registration number 00007772) according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews on 23\u00a0June 2021 [\n                      \n                      ]. The survey protocol is in line with the UK Research Integrity Office\u2019s guidance on good practice in internet-mediated research [\n                      \n                      ]. This online survey was anonymous and did not collect identifiable data on individuals. Participants were provided with a data privacy statement and consented for their responses to be analysed. Further, the study aligned with key principles of the European Pharmaceutical Market Research Association (EphMRA) Code of Practice, including informing respondents in the survey landing page with a clear understanding of the purpose of the data collection, how it will be used (i.e. analysis and publication), anonymity, non-promotion, the right to withdraw, participation is voluntary, and data protection principles [\n                      \n                      ]. Additionally, the study aligns with the key principles of the International Chamber of Commerce (ICC)\/European Society for Opinion and Marketing Research (ESOMAR) International Code on Market, Opinion and Social Research and Data Analytics, including transparent information on what data will be collected, how it will be used and who it may be shared with; and ensuring data protection and ethical behaviour by researchers [\n                      \n                      ]. Participants were informed of the use of the data (as described above) prior to initiating the survey and indicated their consent by continuing to enter and complete the survey. Because the survey collected sensitive information about participants, all data were anonymised from data collection onwards. Participants did not provide names, email addresses or other identifiers, and internet protocol (IP) addresses were never captured within the survey platform. Provided data were handled in line with General Data Protection Regulation (GDPR) guidance [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}